Your study found that analyzing specific bacterial groups in the in the gut could predict melanoma recurrence with a very ...

At the 2026 NCCN Annual Meeting, CURE sat down with Dr. Thomas Flaig to discuss the rapidly evolving landscape of bladder ...

Cancer care is not experienced equally across the globe. Speaking at the 2026 NCCN Annual Conference, Caroline Taylor, ...

Rezetapopt demonstrated a 44.4% overall response rate and durable responses lasting over eight months in patients with ...

Dietitian Stephanie Meyers shared practical strategies at the LiveLung SCLC Patient Summit to help patients manage appetite ...

Gratitude is framed as the central mechanism enabling emotional regulation, meaning-making, and perseverance through colon ...

Rezetapopt showed a 44.4% response rate and durable responses over 8 months in ovarian cancer with p53 Y220C mutation, with mostly mild side effects.

Dietitian Stephanie Meyers shared practical strategies at the LiveLung SCLC Patient Summit to help patients manage appetite loss and digestive issues.

Comorbid MDS, fibromyalgia, and chemotherapy-related ototoxicity complicated symptom attribution, initially obscuring a ...

Dr. Sunil Dutta discusses treatment approaches and managing side effects in esophageal cancer, including nutrition and ...

At NCCN 2026, Dr. Charles Peyton emphasized patient engagement and shared decision-making as expanding treatment options reshape bladder cancer care.

At the 2026 NCCN Annual Meeting, Dr. Charles Peyton spoke with CURE about how a growing number of treatment options is ...